Prof. Koraljka Gall Trošelj, M.D.; Ph.D. is a senior research scientist at the Rudjer Bošković Institute where she established and has been heading Laboratory for Epigenomics. Dr. Gall Trošelj is a Fulbright Scholar who spent two years at the Weill College of Medicine at the Cornell University in New York City. She is the author and co-author of numerous articles, co-Editor of Frontiers of Oncology, Frontiers of Pharmacology and Cancer Cell International. She has been reviewer for many journals in the field of molecular and translational oncology. Her primary research interest is focused on basic research in oncology and functional connections between epigenomic networks and activity of cancer metabolism-related genes. She was also an international adviser and permanent secretary of ICMAN conferences (International Conferences on Mechanisms of Action of Nutraceuticals), which she organized in North Carolina, Israel, Australia and Scotland. She also gave many invitation lectures, in Croatia and abroad.
ALBENA DINKOVA-KOSTOVA is a Professor of Chemical Biology at the University of Dundee School of Medicine (UK). She graduated in Biochemistry and Microbiology from Sofia University (Bulgaria) and obtained her PhD degree in Biochemistry and Biophysics from Washington State University (USA). She subsequently trained in Pharmacology at Johns Hopkins University School of Medicine (USA), where she continues to hold an Adjunct Professor position. She joined the University of Dundee in 2007 as a Research Councils UK Academic Fellow and a research group leader. Her group collaborates with basic scientists and clinicians,and with the pharmaceutical industry. In her research, at the interface of Chemical Biology and Medicine, she is committed to understanding how cells and organisms respond to oxidative, inflammatory, and metabolic stress, and is working towards development of strategies for protection against chronic disease. She was named among the top influential academics in Clarivate’s Highly Cited Researchers 2019, 2020, 2021 and 2022 lists.
Ioannis Trougakos obtained his Ph.D. in Cellular-Developmental Biology from the National and Kapodistrian University of Athens (NKUA), Greece. He has worked as Research Scientist at EMBL, Germany, CBM “Severo Ochoa”, Spain and at NHRF, Athens, Greece; he was also research visitor at EMBL and at the Netherlands Cancer Institute. Dr. Trougakos was elected Research Lecturer at NHRF and currently he serves as Professor and Director of the “Cell Biology” lab at the Faculty of Biology, NKUA. Dr. Trougakos has published articles (>190) in high-ranking journals, chapters in international books and he co-authored an academic book (citations ~19500; h-Index = 45 / i10-index = 129); he is also co-inventor in several patents. His group is funded by private (GR, EU, USA) and public (GR, EU) entities; also, the group participates in contractual activities with the Industry.
Andrey Y. Abramov is a Professor at the Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology. He studies the role of mitochondria, calcium signalling and redox biology in physiology of the Central nervous system and in the mechanism of the pathology of neurodegenerative disorders.
Kattri-Liis Eskla. In 2019, Kattri-Liis graduated her PhD in neuroscience at University of Tartu (Estonia) and discovered the profound influence that hypothermia has on the antioxidant system. During her internship in Emory University School of Medicine (USA), she studied hydrogen sulfide and therapeutic lymphangiogenesis as promising new approaches for the treatment of cardiovascular diseases. In 2021, she began as a visiting researcher at the University of Birmingham (UK) to undertake a collaborative research project on the hypoxic and pseudohypoxic biology and cellular metabolism. In 2020, she became a research fellow in human physiology at the Department of Physiology, University of Tartu, Estonia. Her work has broader implications challenging the status quo in the field of hypothermia. She proposes that the widely accepted view that metabolic depression is mostly accountable for the therapeutic effects of hypothermia is most likely incomplete. Her main focus is understanding mechanisms of hypothermia and reductive stress which will lead to enhanced treatment of hypoxic/ischemic conditions as well as other disorders associated with electron transport chain dysfunction and reactive oxygen species formation.
Marlene Santos (Orcid: https://orcid.org/0000-0001-5020-5942) holds a PhD in Biomedicine, MSc in Molecular Genetics, and a Degree in Pharmacy. She is Adjunct Professor at the School of Health from Polytechnic Institute of Porto, Portugal, where she is the Director of the master’s degree in pharmacy. She is also Invited Investigator at Molecular Oncology and Viral Pathology Group of the Research Centre of the Portuguese Institute of Oncology of Porto, and investigator at Health and Environment Research Center (CISA) from Polytechnic Institute of Porto. Additionally, she has been involved in several national and international projects, as well as COST actions. Her research interests focus on the study of biomarkers of psychiatric and neurological diseases and treatment response outcomes, and her main publications are in the field of Pharmacogenomics and Neuropsychopharmacology.
Ángela Martínez Valverde Instituto de Investigaciones Biomédicas Alberto Sols (CSIC-UAM) Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERdem). Instituto de Investigación Hospital Universitario La Paz (IdiPAZ).
My research career has been focused in molecular metabolism. As PhD fellow (1988-91), I studied insulin/IGF1 actions in brown adipocytes. As postdoc at Cancer Research UK (London, 1991-93), I cloned protein kinase D1, a Ser/Thr kinase that later studies revealed its fundamental role in cancer and recently, in glucose homeostasis. Back to Spain as Assistant Professor at Complutense University of Madrid, I implemented my expertise in signal transduction in unraveling insulin/IGF1 cascades related to proliferation/differentiation of brown adipocytes. From 2002 and as a Senior Scientist at Spanish National Research Council (CSIC), I explored the molecular mechanisms of insulin action in the liver. In 2006, I moved to the Institute of Biomedicine Alberto Sols (CSIC/UAM) where I consolidated my leadership as PI and extended my research to the molecular basis of obesity and non-alcoholic fatty liver disease (NAFLD).
From 2008, I am Principal Investigator at CIBERdem (Spanish network in research on diabetes and related metabolic diseases). In this topic, we studied the impact of insulin resistance, ER stress, autophagy, oxidative stress and inflammation in NAFLD and more recently in hepatic biliary diseases. A step further, we investigate the interactome between liver cells in the NAFLD and biliary disease context. We are currently extending this interactome to the extracellular vesicles field and hepatic progenitor cells. Regarding NAFLD therapeutics, we unravelled the efficacy of a GLP1/Glucagon receptor co-agonist in improving liver regeneration during NASH. In the last 10 years, our lab has also studied the molecular basis of the diabetic complications retinopathy and nephropathy, as well as drug-induced hepatotoxicity. In the context of metabolic alterations induced by chronic drug treatments, we evaluate how antipsychotic medication impacts on whole body metabolism and energy balance.
Vita Dolžan is a Full Professor of Biochemistry and Molecular Biology at the Faculty of Medicine, UL. She investigates the influence of genetic variability in drug metabolizing, antioxidative and inflammatory pathways on disease pathogenesis, disease progression and/or treatment response in several diseases, with particular focus on neurodegenerative and inflammatory diseases as well as cancer. She is particularly interested in development of clinical-pharmacogenetic models that would facilitate the translation of genetic, epigenetic and other molecular biomarkers into clinical practice.
1. Saha S, Buttari B, Profumo E, Tucci P, Saso L. A Perspective on Nrf2 Signaling Pathway for Neuroinflammation: A Potential Therapeutic Target in Alzheimer’s and Parkinson’s Diseases. Frontiers in Cellular Neuroscience. 2022;15.
2. von Otter M, Landgren S, Nilsson S, Celojevic D, Bergström P, Håkansson A, et al. Association of Nrf2-encoding NFE2L2 haplotypes with Parkinson’s disease. BMC Med Genet. 2010;11:36.
3. von Otter M, Bergström P, Quattrone A, De Marco EV, Annesi G, Söderkvist P, et al. Genetic associations of Nrf2-encoding NFE2L2 variants with Parkinson’s disease – a multicenter study. BMC Med Genet. 2014;15:131.
4. Paladino S, Conte A, Caggiano R, Pierantoni GM, Faraonio R. Nrf2 Pathway in Age-Related Neurological Disorders: Insights into MicroRNAs. Cell Physiol Biochem. 2018;47(5):1951-76.
5. Xie Y, Chen Y. microRNAs: Emerging Targets Regulating Oxidative Stress in the Models of Parkinson’s Disease. Front Neurosci. 2016;10:298.
6. Redenšek Trampuž S, Vogrinc D, Goričar K, Dolžan V. Shared miRNA landscapes of COVID-19 and neurodegeneration confirm neuroinflammation as an important overlapping feature. Front. Mol. Neurosci. 2023: 16:1123955.
Katja Kanninen is a professor of Cellular Neurobiology at the A.I.Virtanen Institute for Molecular Sciences, University of Eastern Finland. She defended her thesis on NRF2 in Alzheimer’s disease and is now interested in understanding the interplay between environmental exposures such as air pollutants and NRF2. Her group works with in vivo models of neurodegeneration, and with both human and murine brain cells (primarily astrocytes and neurons), and human olfactory cells. She has published several original and review papers on NRF2, primarily in the context of Alzheimer’s disease.
Isabel Lastres-Becker has more than 20 years of experience in the field of neurodegenerative diseases. Her work is focused on the molecular bases of neurodegeneration related to proteinopathy, neuroinflammation, and oxidative stress. She is the head of the laboratory of “New therapeutic strategies in neurodegenerative diseases: Parkinson’s disease (PD), tauopathies and amyotrophic lateral sclerosis (ALS)”. Since 2008 she has been interested in the implication of the transcription factor NRF2 in neurodegeneration, endorsed by 20 publications in relevant international journals. Her wide research background covers the most prevalent neurodegenerative diseases, looking for reliable markers of progression that can also serve as drug targets for modulating neurodegeneration such as NRF2. She is engaged in developing advanced new drugs and appropriate technology to establish treatments for those diseases, based on NRF2.
Paul Shiels. Paul is Professor of Geroscience at the University of Glasgow. He is a graduate of Trinity College Dublin and received his PhD from Glasgow University. He won an EMBO Long-term Fellowship to work at the Netherlands Cancer Institute. This was followed by a period at the Robertson Center for Biotechnology, before joining PPL Therapeutics, Roslin (1996) where he worked on senescence in cloned animals. He is a founder member of G3, the Glasgow Geroscience Group. Paul has established a reputation in the field, developing the kidney as a model of ageing, and is author of over 198 peer reviewed publications and a number of Patents in this sector. Paul has acted as an expert on the Biology of Ageing on national policy advising consortia including pSoBiD, for the Chief Medical Officer of Scotland, and provided evidence to the UK All Party Parliamentary Group on Longevity. He is currently Chair of the Scientific Advisory Board for the British Society for Research on Ageing. His research has involved determining exposome factors (socio-economic, psychological, lifestyle and nutrition) and (epi)genomic factors that are required for healthy ageing. He was the first to report on socioeconomic status and nutritional factors affecting epigenetic influences on health. His current research portfolio comprises investigation and application of novel senotherapies, biomimetics and how the microbiome impacts on age related health.
Paul has acted as CSO for Pathfinder Cell Therapy PLC and has been funded by, acted as a consultant for and sat on the Scientific Advisory Boards of a wide range of Pharma companies. He has a proven track record in public dissemination of his research including the provision of expert commentary for the BBC and ABC TV networks and as a Panelist at the Edinburgh International Science Festival and the Edinburgh International Book Festival.
Silvia Silva-Hucha: I obtained my PhD in neurosciences at the University of Seville (2020). Afterwards, I joined the Professor Steve Hunt’s group at the University College London with a project funded by the Medical Research Council. My pre and postdoctoral career has given me experience in the study and treatment of neurodegenerative diseases, and the important role of the VEGF trophic factor in establishing differential resistance to motor neurons. Last March 2023. I joined the Jordi Muntané’s lab in the Institute of Biomedicine of Seville to elucidate the molecular mechanisms of action of first line therapies for the management of patients with advanced HCC.
Gerasimos (Gerry) Sykiotis is Senior Staff Physician at Lausanne University Hospital and Associate Professor at the University of Lausanne. He specializes in clinical and basic endocrinology with a particular focus on thyroid physiology and thyroid diseases, including thyroid cancer. Since 2015, he is responsible for the thyroid clinic at the Endocrine Division of Lausanne University Hospital. His basic research, funded primarily by the Swiss National Science Foundation, focuses on the roles of cellular antioxidant response systems in thyroid physiology and pathophysiology. His clinical research focuses on the needs of patients with benign and malignant thyroid diseases.
Srđan Bjedov is an assistant professor at the Department of Chemistry, Biochemistry and Environmental Protection, Faculty of Sciences, University of Novi Sad, Serbia. His research is focused on the synthetic and medicinal chemistry of mainly steroid compounds for the treatment of inflammatory, microbial, and cancer diseases.
Ana Sofia Falcão holds a PhD in Pharmacy since 2006 and she is currently working as a post doctoral researcher at the Molecular Mechanisms of Disease Lab, at Nova Medical School (NMS), from Universidade Nova de Lisboa. At NMS, she became interested in exploring innovative therapeutic approaches for neurodegenerative disorders or other age-related diseases, such as AMD. She is focused on in vitro systems to study retinal pigment epithelial cells that will be used for fundamental studies as well as for potential translational applications to treat retinal disorders.
Silvia Giordani joined the School of Chemical Sciences at Dublin City University as Professor Chair of Nanomaterials in 2018 and took on the role of Head of School in 2020. Previously she received her PhD in Chemistry from the University of Miami, USA and carried out postdoctoral research at Trinity College Dublin (TCD) and at the University of Trieste, Italy. In 2007 she received the prestigious President of Ireland Young Researcher Award and was a Research Assistant Professor at TCD from 2007 to 2013. In 2013 she founded and directed the new “Nano Carbon Materials” research lab at the Istituto Italiano di Tecnologia (IIT) and in December 2016 she was appointed Associate Professor in Organic Chemistry at the University of Turin, Italy. Her main research interests are in the design, synthesis, and characterization of a wide range of nanomaterials for applications in smart and responsive bio-related nanotechnologies. She is the author/co-author of more than 140 manuscripts, reviews and book chapters. She is the recipient of many international prizes and honours including the L’Oreal UNESCO for Women in Science fellowship, the William Evans visiting fellowship from the University of Otago (New Zealand) and is a Visiting Scientist to the Bio-Nano Institute at Toyo University (Japan). Her research has been recently featured in “Where I work” published in Nature on the 20th May 2021.
Antonio Cuadrado, is full professor of Biochemistry and Molecular Biology at the Department of Biochemistry, Medical School, Autonomous University of Madrid. He obtained his PhD degree in Biology in 1985 and enjoyed several postdoctoral stays in the National Cancer Institute-NIH with the help of Fulbright and Fogarty fellowships. He established his independent laboratory as Professor of Biochemistry in 1997 with a main interest on the study of molecular mechanisms involved in initiation and progression of chronic diseases. For the past years his main lane of research has been the validation of transcription factor NRF2, master regulator of cellular homeostasis as a new therapeutic target in chronic diseases with particular emphasis in neurodegenerative diseases (Alzheimer and Parkinson) and in fatty liver diseases. His current interest is the development of new NRF2-modulating drugs. Dr. Cuadrado has published over 160 primary and review articles, of which more than 80 are related to the role of NRF2 in physiological and pathological responses to disease.
Nesrin Kartal Ozer, is Professor at Marmara University, Faculty of Medicine, Department of Biochemistry, Istanbul,Turkey. She graduated with a BSc in Pharmacy from Hacettepe University, Ankara, Turkey and she has received her PhD in Biochemistry in Hacettepe University, Faculty of Medicine. She moved then to Marmara University, Istanbul. She was a Visiting Scientist at St.George’s Hospital, Medical School, Department of Biochemistry, London, UK (1985-1986); Institute of Biochemistry and Molecular Biology, University of Bern, Switzerland (1993-2004) and University of Hohenheim, Stuttgart, Germany (2008).
In her research she published ~ 100 articles and she was invited speaker at ~80 international meetings. She was the organizer ~10 scientific meetings and conferences.
As member of International Organizations, it is worth mentioning her membership in the International Advisory Committee, Oxygen Club of California (1999- today); FEBS Advanced Course Committee Member (2003-2006); FEBS Fellowships Committee Member (2021-2024), Secretary General Society for Free Radical Research-Europe (SFRR-E) and Member of the Council (2003-2009) and President of SFRR-E (2013-2014).
She was awarded The Oxygen Club of California Award and “Life Time Honorary Member” in 2006 “In recognition of outstanding research contributions on the role of vitamin E in atherosclerosis and to fostering the field of free radical biology” and The Society for Free Radical Research-Europe Lifetime Achievement Award in 2019 “In recognition of Lifetime Extraordinary Scientific Achievements in the Field of Free Radical Research”.
Her research focus on endoplasmic reticulum stress, redox signaling and cell death in metabolism related diseases such as cardiovascular diseases and non-alcoholic fatty liver disease. In parallel she has carried out research on the molecular function of tocopherols in these diseases.
Santiago Cuevas. 22 years of experience in the academy and industry in basic, translational and clinical research studying the pathways involved in the regulation of oxidative stress and inflammation in the pathogenesis of hypertension, cardiovascular and renal diseases. Ten years of research experience in the United States on the field. At the present, I am a Principal Investigator Miguel Servet in the Institute of Biomedical Research in Murcia (IMIB). I am a team leader in the Unit of Molecular Inflammation at the IMIB led by Dr. Pablo Pelegrin, where we study the molecular mechanism involved in inflammasome regulation and its role in the pathogenesis of several diseases.
Jelizaveta Sokolovska, MD, PhD, internist, endocrinologist is a practicing clinician and leading researcher at the University of Latvia. She has scientific expertise in the field of diabetes, complications of diabetes, endocrinology, clinical research, nutrition. Current scientific directions include biomarkers in diabetic retinopathy and nephropathy; intestinal inflammation and microbiome changes as a potentially modifiable risk factor for complications in type 1 diabetes; application of artificial intelligence methods for patient stratification in monitoring and prevention of diabetic complications; lifestyle and diet for prevention of diabetic complications.
Juan Antonio Moreno is a Ramon y Cajal Tenure Track Researcher at the Department of Cell Biology, Physiology and Immunology (Cordoba University, Spain). Head of the Group GE-06 “Pathophysiology of renal and vascular damage” at Maimonides Research Institute of Cordoba (IMIBIC). My group is unravelling novel pathogenic mechanisms involved in the development of renal and vascular diseases (atherothrombosis, diabetic nephropathy, glomerular diseases, acute kidney injury, renal fibrosis, among others). We aim to understand the basis of the alterations occurring in both kidney and arterial wall by targeting specific pathways to decrease the progression of these pathologies. Specifically, we are interested in certain cellular and molecular mechanisms, such as oxidation, inflammation, apoptosis and fibrosis. In the last years, we have evaluated the role of Nrf2 in acute kidney injury and are interested in the validation of novel compounds targeting Nrf2 to decrease both renal and vascular damage.
Virginijus Tunaitis is a Senior research associate at the Department of Stem Cell Biology, Centre for Innovative Medicine, Vilnius. His research is focused on the human mesenchymal stem cells (MSCs)-derived extracellular vesicles and neurodegenerative disease modeling in vitro.
Anna-Liisa Levonen is currently Professor and Vice Dean of Research at the University of Eastern Finland, Faculty of Health Sciences. She is also Associate Editor of Redox Biology. She earned her MD and PhD degrees from the University of Helsinki, Finland in 1994 and 2000, respectively, followed by a fellowship at the University of Alabama at Birmingham (UAB), Department of Pathology and Center for Free Radical Biology. Upon her return to Finland, she was recruited to the University of Kuopio (currently University of Eastern Finland), where she has established a research program focusing on the gene regulatory mechanisms activated by oxidative and electrophilic stress, particularly via the redox-activated transcription factor NRF2. She has studied the mechanism of activation of the KEAP1-NRF2 pathway and its role in disease, particularly cancer and cardiometabolic diseases, and has published highly cited original and review articles on the topic.
Aleksandra Buha Djordjevic is an associate professor of Toxicology at the Department of Toxicology, University of Belgrade – Faculty of Pharmacy. Her main research interest is the toxicology of mixtures and endocrine-disrupting chemicals. In the field of NRF2 signaling, her special interest is in the role of this pathway in the toxicity of environmental toxicants. She is the author/co-author of more than 80 peer-reviewed publications, her h index is 26 and her work has been cited more than 2000 times according to SCOPUS. Dr. Buha Djordjevic has been included in the Stanford University list of top 2% scientists in the world for 2020 and 2023. She is a MC member and science communication coordinator COST action CA 20121 „Bench to bedside transaction for pharmacological regulation of NRF2 in noncommunicable diseases“.
Michel is assistant professor focusing on immunology at the Institute of Genetics and Animal Biotechnology of the Polish Academy of Sciences (IGHZ) at the department of experimental genomics. Prior to starting his tenure as an assistant professor, Michel was trained as a postdoc at Uppsala University, Sweden; UKE, Hamburg, Germany; and the Victor Babes Institute, Romania. He worked as a visiting scientist at UAB in Alabama. Prior to that, he earned his PhD from Durham University. Michel research is dedicated to understanding the role of the adaptive immune system in neuroinflammatory diseases on a single-cell level. One aspect of his research focuses on the gut-brain axis during colorectal cancer and colitis. In particular, Michel is interested in studying the CD4+ Th17/Treg network and its role in linking microbiota, dietary components, and brain inflammation during colitis and colorectal cancer. To study this interesting biological landscape, various immunological assays are employed, including sorting of CD4+ T cell subtypes using flow cytometry, in vitro assays (differentiation and co-culture), and in vivo assays (adoptive transfer). Michel’s interests span both basic immunology animal research and translational human-based research. Michel is also an expert in using cutting-edge computational methods such as next-generation sequencing, including RNA-seq, CHIP-seq, and single-cell RNA-seq (10x and Dropseq), as well as AI mining of TCR-microbiota species data. An important aspect of Michel’s work is teaching various academic courses. Furthermore, Michel is supported by various national and international grants.
Andreas Daiber studied Chemistry at the University of Konstanz (Diploma in 1997), holds a PhD in Biochemistry (graduated in 2000), did his habilitation (graduated in 2006), and since 2008 is a full professor in Molecular Cardiology at the University Medical Center Mainz. >33 significant research grants from the pharmaceutical industry and public funding bodies. 2011 guest professorship at the Université Joseph Fourier at Grenoble, France. From 2014-2016 Chair of COST Action BM1203 (EU-ROS). Memberships in national and international scientific communities (SFRBM/SFRRE, ASBMB, DGK), reviewer activities for numerous scientific journals (e.g. FRBM, Redox Biology, ATVB, Eur. Heart J., Nat. Comm.) and funding bodies, editorial board positions (Oxid. Med. Cell. Longev., Cardiovasc. Res., Antioxidants, FRBM, Redox Biology), guest editor (Antioxid. Redox Signal., Redox Biology, Br. J. Pharmacol., FRBM, Antioxidants). He published >195 original research articles, >150 review articles, 26 book chapters, >180 conference abstracts and 3 patents with Boehringer Ingelheim. h-index: 75; >16,600 citations. Special research interests: redox biochemistry, oxidative stress and environmental research in cardiovascular disease.
Iveta Bernatova is a senior scientist, Head of the Department of Experimental Hypertension and a Member of the Management Board of Centre of Experimental Medicine, v.v.i., Slovak Academy of Sciences, Bratislava, Slovakia. She studied Biochemistry (Diploma in 1991), holds PhD in Chemistry (1997) and a title Doctor of Science (D.Sc.) in Animal Physiology (2009). Her research is focused on the regulatory mechanisms of blood pressure in various experimental models of hypertension and the ways of prevention and treatment of high blood pressure with particular attention paid to the role of nitric oxide and oxidative stress in the regulation of blood pressure and vascular function. A significant part of her research is focused on the role of chronic social stress in the development of hypertension and on mechanisms of adaptation to stress. The most recent studies are focused on the research of iron metabolism in the heart and liver, the role of NRF2 in the regulation of iron metabolism in rats with various genetic predispositions to hypertension as well as on the effect of acute and chronic stress in NRF2-mediated mechanisms. She is the author of 120 peer-reviewed publications with around 2000 citations.
The study was supported by project VEGA No. 2/0157/21.
Elena Milanesi is Assistant Professor at the Faculty of Medicine Carol Davila of Bucharest and researcher at the National Institute of Pathology Victor Babes, Bucharest, Romania. She studied Medical Biotechnologies at the University of Brescia Italy, where she holds a PhD in Molecular Genetics Applied to Medical Sciences (2012). She worked two years at the Sackler Faculty of Medicine of Tel Aviv, Israel as Post-Doc. Currently, she is Principal Investigator of the ICRP/ICGEB project “The brain-gut axis linking inflammatory bowel disease with anxiety and depression: the inflammation-microbiome network” (2022-2024) and principal Investigator of the project “The regulatory effect of miRNAs on redox and inflammatory alterations identified in cognitive impairment” funded by the national fellowship program L’Oreal – Unesco “For Women in Science” (December 2022-2023). Since October 2021 she is Gender Equality Officer and from February 2023 GH Manager of the COST ACTION CA2012.
Vicente Miguel is a trainee working in Sandra Tenreiro’s DEGENERATION AND AGEING research group that focuses on clarifying the molecular mechanisms of retinal degeneration in the context of ageing diseases, using cellular models RPE and 3D retinal organoids, differentiated from human iPSc. VM is a 3rd-year bachelor’s student in biology with a specialization in genetics and molecular biology at Faculdade de Ciências da Universidade de Lisboa (FCUL) and has a particular interest in the fundamental and mechanistic study of Ageing. Vicente won the ‘New Talents’ scholarship from the Calouste Gulbenkian Foundation in late 2022 and has since worked in ST’s group.
Miriam Sánchez studied Health Biology at the University of Alcalá (2016) and hold a PhD in Molecular Biosciences at the University Autonomous of Madrid (2023) under the supervision of Dra. Ana Clara Carrera and Dr. Antonio Garrido. During these years, she has been focusing on lung cancer, trying to find novel therapeutic targets for lung squamous cell carcinoma related to NRF2/KEAP1 pathway.
Monika Mlinarić is a PhD student working in the Laboratory for Oxidative Stress, Division of Molecular Medicine at Ruđer Bošković Institute. She is working on the project “Elucidating the role of aquaporins 3 and 5 in the development of breast cancer resistance to oxidative stress (AquaBCaRe)” with Dr. Lidija Milković and Dr. Ana Čipak Gašparović. As a topic of her PhD, she will investigate the interaction of Nrf2 and aquaporins (channels that facilitate the transport of hydrogen peroxide across the membrane), as well as their response to the state of chronic oxidative stress.
Ivan Lučić is a PhD student working in the Laboratory for Oxidative Stress, Division of Molecular Medicine at Ruđer Bošković Institute. Although his background is limited as he just started working, he has been actively involved in several research projects. His master’s thesis focused on the interaction between aquaporin 3 and the EGFR/PI3K/AKT signaling pathway in breast cancer cell lines. For his PhD research, he will further investigate the relationship between breast cancer, oxidative stress, and NRF2.